Navigation Links
Surveyed U.S. Neurologists Report Greater Overall Satisfaction with Tecfidera than with Platform Injectables and Other Oral Multiple Sclerosis Therapies

EXTON, Pa., Sept. 24, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed U.S. neurologists report significantly greater overall physician satisfaction with Biogen Idec's recently-launched oral disease-modifying therapy (DMT) Tecfidera than with most other DMTs approved for the treatment of relapsing forms of multiple sclerosis (MS). These other agents include platform injectables such as interferon-beta therapies and Teva's Copaxone, as well as other oral DMTs—Aubagio from Genzyme (a Sanofi company) and Novartis's Gilenya. This finding likely reflects respondents' high rating of Tecfidera on several key performance attributes in the areas of efficacy and patient benefits compared with other approved agents. Nevertheless, Copaxone—the current patient share leader among respondents' DMT-treated MS patients—still ranks as respondents' most preferred brand for the treatment of relapsing-remitting multiple sclerosis (RR-MS), a perception driven by the drug's long-term safety and tolerability/side effect profile.

(Logo: )

The recently published TreatmentTrends: Multiple Sclerosis Q3 2013 (US) report also finds that, if only two late-stage emerging products were to launch for the treatment of MS (out of six products assessed), more than 45 percent of surveyed neurologists select Teva's Copaxone 40 mg three-times-weekly (3TW) and Genzyme/Bayer HealthCare's Lemtrada as bringing the most value to treatment; slightly fewer also chose Teva/Active Biotech's laquinimod. Data show that neurologists' self-reported familiarity with the product and its predecessor drives the perceived value of Copaxone 40 mg 3TW, while efficacy and administration, respectively, are the most frequently-cited reasons for respondents' perceived value of Lemtrada and laquinimod.  

The findings also reveal that surveyed neurologists expect total patient share for oral DMTs—Aubagio, Gilenya, and Tecfidera—to increase significantly among DMT-treated RR-MS patients over the next six months, mainly at the expense of the interferon-beta brands and Copaxone. During this time, neurologists expect the overall patient share for oral DMTs to more than double from 14 percent to 30 percent overall, with most of this growth coming from anticipated use of Tecfidera. Use of Biogen Idec's Tysabri, which ranks highest on multiple efficacy and other key performance attributes, is also expected to increase significantly.

"With the advent of oral DMTs and new DMT alternatives on the horizon for the treatment of MS, surveyed neurologists indicate further change in clinical practice is coming," said Senior Director of CNS Disorders Jonathan W. Searles. "As part of this change, our findings signal neurologists' continued reliance on products demonstrating strong safety, but also a growing acceptance of agents that offer robust efficacy at potentially greater risk, if such risks are defined, manageable, and clinically justified."

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients
2. A Significant Share of Surveyed Treatment-Naive and Prior Failure HCV Patients Plan to Initiate an HCV Treatment Regimen in the Next Year
3. Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen Idecs Tecfidera to be a Breakthrough in the Treatment of Multiple Sclerosis
4. Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinsons Disease on Their Largest Commercial Plan
5. The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
6. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
7. Surveyed U.S. and European Neurologists Identify Better Seizure-Free Efficacy as One of the Greatest Unmet Needs in Treating Partial-Onset Seizures in Refractory Epilepsy Patients
8. One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs
9. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
10. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
11. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
Post Your Comments:
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
(Date:6/23/2016)... , June 23, 2016 ... "Surgical Procedure Volumes: Global Analysis (United States, China, ... Canada)" report to their offering. ... essential tool for healthcare business planners, provides surgical procedure ... at surgery trends with an in-depth analysis of growth ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in ... ways they remain in the eye of the beholder, according to experts who offered ... The American Journal of Managed Care. For the full issue, click here . ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
Breaking Medicine News(10 mins):